CLPT
$9.03-0.15 (-1.63%)
ClearPoint Neuro, Inc.
Recent News
ClearPoint Neuro Q4 Earnings Call Highlights
ClearPoint Neuro (NASDAQ:CLPT) reported higher revenue for both the fourth quarter and full year 2025 and outlined a two-phase growth strategy that management said is designed to expand the company’s presence across multiple neurosurgical markets while positioning for longer-term opportunities in ce
ClearPoint Neuro, Inc. Q4 2025 Earnings Call Summary
Moby summary of ClearPoint Neuro, Inc.'s Q4 2025 earnings call
ClearPoint Neuro (CLPT) Earnings Call Transcript
Joseph Burnett: Thank you. This is one of the largest unmet needs in all of medicine, and we at ClearPoint Neuro, Inc. believe we can play a crucial role in this exciting future. This foundation is made up of four growing product categories, a vetted pipeline of new development programs, an expanded manufacturing footprint, a thoroughly audited quality system, a collection of global regulatory approvals, an expansive IP portfolio, an installed base of more than 150 global centers, and the cash position and investor base to execute on our strategy.
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -22.73% and +7.32%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro Inc (CLPT) Q4 2025 Earnings Report Preview: What To Expect
The consensus estimate for Q4 2025 revenue is $10.05 million, and the earnings are expected to come in at -$0.20 per share. The full year 2025's revenue is expected to be $36.60 million, and the earnings are expected to be -$0.83 per share. More detailed estimate data can be found on the Forecast page.